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Abstract. Immunoinformatics is the one of bioinformatics divisions. The focus of this 
division is to design compounds of immune response activists or candidate vaccine in silico or 
computation. One type of immune response activator compound is a peptide. Peptides are 
small amounts of amino acid residues. The amount of amino acid residues that can activate 
the immune response ranges from 9-15 amino acids. Good candidate vaccine quality is shown 
affinity or strong bond between peptide and MHC (Major Histocompatibility Complex) is 
indicated by the value of energy of molecule-blocking process through low software. This 
research is conducted in Data and Process Laboratory of Biology Department, Faculty of 
Science and Technology, States of Islamic University Sunan Gunung Djati Bandung, in 
December 2016 until February 2017. The study amis to get candidate vaccine ebola peptide 
form 9 (nine) amino acid residues. The tool used in this research is the software which made 
based on the working principle of immune response. The software is SDS Workbench, IEDB-
AR, Emboss, and CABSdock. The material used in this research is the sequence information 
of ebola virus glycoprotein. The results show that the peptides with FLYDRLAST 
(Fenilanalnin, Leusin, Tyrosine, Aspartic acid, Arginine, Leusin, Alanine, Serin Treonin) are 
potential candidate for the ebola peptide vaccine because of their high affinity values with 
MHC I, indicated by molecular-binding energy which is very low ie -1870.69 Kcal / mol.  
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1. Introduction 
Ebola disease grows rapidly in Africa1,2. In human, this disease causes severe bleeding in the 
body even the death rate of patients reaches 90%3,4. Every year, cases and deaths from ebola 
disease continue to increase. In 2016, WHO recorded from 28,638 cases of ebola disease, the 
death rate reached 11,316 people5. 
The ebola disease is caused by five ebola species that have different mortality impacts 
on humans ie Zaire ebolavirus, Sudan ebolavirus, Tai Forest ebolavirus, Reston ebolavirus6 
and Bundibugyo ugolavirus1,2,3. The species of Zaire ebolaviruses are the most pathogenic 
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species with mortality rates around 80%3. Prevention of this disease can be done with the 
vaccine3. 
The design of epitope/peptide based vaccine candidates using immunonformatics has 
been widely developed4,7. Epitopes are a minimal part of the antigen that can induce the 
immune system8. Epitope-based vaccines have many advantages such as more effective, 
more efficient, and the process is short for one to two years9. The immunoinformatics 
approach begins with the determination of the genome sequence and proceeds by predicting 
the antigen most likely to be used as a vaccine candidate from the genome sequence10. 
The ebola virus is composed of genomes consisting of nucleoprotein (NP), protein 
structural virion (VP) VP35, VP40, glycoprotein (GP), VP30, VP24 and RNA-dependent 
RNA polymerase (L)3. From the genome structure of the ebola virus, the glycoprotein gene 
(GP) is the most potential gene to be used as a source of ebola vaccine candidates. This is 
because GP in the ebola virus is the only surface protein of the virus and is very important in 
the process of attachment to the host cell and catalyze the occurrence of membrane fusion2. 
The immune response of the body is triggered by the entry of antigens or 
microorganisms into the body and is confronted by macrophage cells which will subsequently 
play the antigen presenting cell (APC). These cells will capture small amounts of antigens 
and are expressed to the surface of cells that can be recognized by T lymphocytes cells (Th or 
T helper). These Th cells will be activated and will activate other lymphocytes such as B 
lymphocytes or cytotoxic T lymphocytes. T cells only recognize immunogens which attaches 
to the MHC protein (Major Histocompatibility Complex) on the surface of another cell19. 
Proteins that interact with MHC is what can be used as a candidate vaccine because it can 
induce the immune system process.  
One of the main conditions in designing epitope vaccines through the 
immunoinformatics approach is that there should be no part of the homologous candidate 
vaccine source sequence / similar to the human genome sequence, since it is feared that if the 
vaccine is made from a homologous candidate source with the human genome, the vaccine 
will cause the disease autoimmune11. The next important stage of vaccine candidate design is 
the determination of the antigen binding affinity of peptides / epitope on MHC molecules7 
Furthermore, peptide-MHC interaction analysis was done through molecular blocking 
process. This method is expected to obtain potential candidate vaccine peptide sequence. 
 
2. Methods 
The sequence of glycoprotein amino acid is obtained from the uniprot.org website. The 
sequence is then analyzed homologically with the human genome using SDSC (San Diego 
Supercomputer Center) Biology Workbranch - TFASTY. The quality of the protein bonds 
was then analyzed using MHC I using the program of IEDB-AR (Immune Epitope Database-
Analysis Resources)12,13. The bonding and interaction analysis between MHC I-peptides and 
molecular-binding methods using the CABSdock program14 and BIOVIA Discovery Studio 
Visualizer Version 4.5 was performed. 
 
3. Results and Discussion 
Homology or similarity can be seen based on statistical estimates called percent-likeness. The 
commonly used rule is that two sequences are said to be homologous if they have a> 30% 
equilibrium16. The result of homology analysis using SDSC Biology Workbranch program 
based on TFASTY showed that glycoprotein (GP) gene had a percent value of 25.15% with 
human genome (<30%). This shows that GP is can be used as a source of vaccine 
candidates.TFASTY is a part of fasta3 which contains a program of searching the DNA or 
protein sequence. TFASTY has a function to compare the amino or DNA sequences with 
DNA in the database. 
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The design of an epitope vaccine candidate is done by predicting the peptide sequence of the 
GP ebola gene that is strongly bound to MHC I. This prediction is made using the IEDB-AR 
program. The results of the analysis by IEDB-AR are IC50 values (Inhibitor Concentration 
50) in nM. In the program there are provisions, ie peptides with IC50 values <50 nM are 
considered to have a high affinity, <500 nM (intermediate affinity) and <5000 nM (low 
affinity). 
The IEDB-AR program uses three algorithm models to predict the IC50 value of 
Artificial Neural Network (ANN), Strabilized Matrix Method (SMM)14 and Combinatory 
Library Sidney 2008 (comblib_sidney2008)16. ANN is a computer algorithm model with a 
simple processing system, where the system is able to transmit a signal if it receives a strong 
input signal16. In the SMM method, IC50 is calculated based on the MHC peptide position-
specific score matrix13. It consists of a prediction process that resembles the work of neural 
networks with various coding schemes of specific bonding codes13. Comblib_Sidney2008 
refers to a set of predictors (ie scoring matrices) derived from affinity measurements of 
peptide binding combination to the MHC alleles panel16. For the conclusion of the results, the 
IEDB-AR program displays them in a percentile rank, where small number percent rank 
values indicate a high affinity17.. Here are 5 peptide sequences that have the smallest 
percentile rank of IEDB-AR analysis results in GP ebola genes (Table 1). 
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Based on Table 1, peptides with the best affinity for MHC I are peptides in the order of 
FLYDRLAST (phenylalanine, leucine, tyrosine, aspartic acid, arginine, leucine, alanine, 
serine, threonine) since they have the smallest percentile rank value (0.4)19  with IC50 value 
8.14 (ANN) 26.80 (SMM) and 5,07x106 (comblid_sidney2008). 
The molecular blocker is performed to visualize the affinity between FLYDRLAST 
peptide and MHC I. Through this method it is known that molecular interactions occur 
between specific FLYDRLAST peptides, specifically. Molecular tacking is done with the 
CABSdock program. Some of the things that are done on the molecular blocking process are 
the prediction of the active side bonding on the receptor structure, peptide modeling on the 
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active side and the refinement of the protein-peptide bond14. Here are the results of 
FLYDRLAST peptide molecules with MHC I HLA * A 2: 1 allele (Figure 1). 
 
Figure 1. Molecule interaction between FLYDRLAST peptide and MHC I (PDB 2X4U 
Code) 
 
Table 2. Non-Kovalen interaction between Amino Acide of Peptide FLYDRLAST and MHC 
I. 
Amino Acid 
Distance (Å) Type of Interaction 
Peptide MHC 
ASP186 ARG97 3,97 Hydrogene bond, Electrostatics 
SER190 THR73 3,13 Hydrogene bond 
ASP186 ARG97 3,06 Hydrogene bond 
ALA189 HIS114 2,85 Hydrogene bond 
ASP186 HIS70 4,17 Electrostatics 
THR191 TYR116 4,46 Electrostatics 
ALA189 HIS114 3,28 Hydrophobic  
LEU188 LEU156 3,68 Hydrophobic  
ALA189 TRP133 4,78 Hydrophobic  
ALA189 TRP147 4,27 Hydrophobic  
 
 
The quality of molecular binding depends on the value of RMSD (Root Mean Square 
Deviation). Molecular binding qualities are categorized as good if RMSD values <3Å, 
medium quality when 3Å ≤ RMSD ≤ 5.5 Å and low quality when ≥5Å14. To find out the 
quality of the binding is done validation method. Validation is done by molecular binding on 
the three-dimensional structure of ligand receptor (peptide-MHC) contained in the database 
(GDP). The CABSdock program generates a RMSD value of 2.15 Å. This value indicates 
that the quality of molecular blockers is of good quality. 
Figure 1 shows the visualization of the affinity that occurs between the FLYDRLAST 
peptide and MHC I. This affinity is clarified by the molecular interaction information 
between the peptide against MHC I in the range of 5 Å (Table 2). Figure 2 shows four 
hydrogen bonds, three electrostatic interactions and four hydrophobic interactions. 
Conventional hydrogen bonds are formed between SER190-THR73 and ASP186-ARG97. 
Hydrophobic interactions involving an alkyl group are formed between LEU188-LEU156, 
ALA189-TRP133 and ALA189-TRP147. Other interactions involving sigma-Pi or Pi-Pi 
orbitals are formed by ASP186-HIS70, THR191-TYR116 and ALA189-HIS114. The free 
energy produced by the bond between the FLYDRLAST peptide and the MHC I of the 
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molecules is -1870.69 Kcal / mol. This value is very low, so the FLYDRLAST peptide has a 
strong affinity for MHC I 14. A strong affinity between peptide and MHC I may induce 
cytotoxic T cells11. With induced cytotoxic T cells then the infected cells can be killed18. The 
activated immune system process indicates that the peptide is a potential epitope candidate 




The sequence FLYDRLAST (Phenylalanine, Leusin, Tyrosin, Aspartic Acid, Arginin, 
Leucine, Alanine, Serine, Threonine) is the most potential sequence of glycoprotein zaire 
ebolavirus for ebola vaccine 
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